African Cancer Genome: GMD

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Fox Chase Cancer Center
Study ID
NCT05754658
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Standard of Care — OTHER
    Drugs routinely administered for breast cancer per local standard.
  • Standard of Care — OTHER
    Drugs routinely administered for prostate cancer per local standard.

Study Details

The goal of this study is to develop a comprehensive characterization of genetic and molecular drivers of breast and prostate cancer in individuals of African ancestry. The study is conducted by the African Caribbean Cancer Consortium (AC3) and involves the recruitment of patients from nine international AC3 research sites in the Bahamas, Barbados, Benin, Burkina Faso, Haiti, Jamaica, Kenya, Namibia, and Trinidad and Tobago, and the US. The main questions are to: molecularly characterize genomic changes in the African Cancer genomes of the breast and prostate and identify the effects of social determinants of health and lifestyle factors on mutational landscape. Black individuals that have been diagnosed with pathologically confirmed prostate or breast cancer will be included. Detailed social determinants of health survey, blood and archived FFPE tissues will be collected. (Tier 1) All patient tissues will be subject to IHC for receptor status (ER, AR, PR Her2/neu). All patients with available germline DNA from blood will receive genetic screening using a Commercial gene panel testing. (Tier 2) Patient samples with a negative genetic screening will be subject to whole exome sequencing or banked for later RNA or methylation sequencing.

Key Dates

Start date
Nov 28, 2022
Status verified
Aug 2025
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025

Study Design

Enrollment
1,500 participants (estimated)

Arms

  • Arm: Breast Cancer
    Female patients
  • Arm: Prostate Cancer
    Male patients

Primary Outcome Measure

Immunohistochemistry [ Time Frame: Year 1-2 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Fox Chase Cancer CenterPhiladelphiaPennsylvania19111
CAMILLE RAGIN, PhD, MPH
[email protected]
215-728-1148
SOPHIA GEORGE, PhD
[email protected]

Find similar trials in Philadelphia, PA

By condition
Breast cancerProstate cancer
By specialty
OncologyBreast oncologyWomen's healthProstate oncologyMen's healthUrology
By research site
Fox Chase Cancer Center· Philadelphia, PA

Related Studies